BioSpace News Archive

Business

Nanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update

Nanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update.

March 31, 2022
·
21 min read
Biotech Bay

Renegade.bio Announces Decision to Continue No-Cost COVID-19 Testing for Symptomatic, Uninsured Bay Area Community

Renegade.bio Announces Decision to Continue No-Cost COVID-19 Testing for Symptomatic, Uninsured Bay Area Community.

March 31, 2022
·
2 min read
Drug Development

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

Evolus Announces First Patient Enrolled in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau.

March 31, 2022
·
5 min read
Pharm Country

Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility

Marinus Pharmaceuticals , Inc. today announced it has received $30 million in funding under the existing Oaktree Capital Management, L.P. (Oaktree) credit agreement.

March 31, 2022
·
5 min read
Deals

Acer Therapeutics Regains Compliance with Nasdaq Listing Standard

Acer Therapeutics Inc. today announced that it has received notice from The Nasdaq Stock Market (Nasdaq) on March 30, 2022 informing Acer that it has regained compliance with the minimum market value of listed securities standard under Nasdaq List Standard.

March 31, 2022
·
1 min read
Drug Development

HMNC Brain Health and Develco Pharma Announce Promising Preliminary Results in TRD, suggesting antidepressant efficacy and showing Placebo-Level Dissociative Side Effects in Phase 2 oral prolonged-release Ketamine (KET01) Study

HMNC Brain Health announced promising top-line results from the Phase 2 Proof-of-Concept investigator-initiated trial of its oral prolonged-release formulation of ketamine in Treatment-Resistant Depression.

March 31, 2022
·
7 min read
Business

Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to its Scientific Advisory Board

Sigyn Therapeutics, Inc. today announced the appointment of Ajay Verma, M.D., Ph.D.to its Scientific Advisory Board.

March 31, 2022
·
4 min read
GADOPICLENOL: ANOTHER MILESTONE ACHIEVED

Bracco is very excited about the Priority Review granted by the U.S. Food and Drug Administration (FDA) to the New Drug Application (NDA) of the investigational high-relaxivity, macrocyclic gadolinium-based contrast agent (GBCA) Gadopiclenol.

March 31, 2022
·
3 min read
Business

Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Tenax Therapeutics, Inc. today reported financial results for the year ended December 31, 2021 and provided a business update.

March 31, 2022
·
10 min read
Drug Development

New Analysis Finds UPLIZNA® (inebilizumab-cdon) Effective for People with Newly-Presenting Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of a post-hoc analysis from the N-MOmentum Phase 3 pivotal trial of UPLIZNA, showing that the medicine was safe and effective in NMOSD patients who were treated with UPLIZNA after having only one attack.

March 31, 2022
·
10 min read